Active surveillance in intermediate risk prostate cancer: is it safe?

Active surveillance in intermediate risk prostate cancer: is it safe?

Bibliographic Details
Main Authors:	Nishanth Krishnananthan, Nathan Lawrentschuk
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia 2016-06-01
Series:	International Brazilian Journal of Urology
Subjects:	Prostatic Neoplasms Prostate cancer familial [Supplementary Concept] Watchful Waiting Disease Therapeutics
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382016000300418&lng=en&tlng=en

Similar Items

Active surveillance in intermediate risk prostate cancer: is it safe?
by: Henk G. van der Poel, et al.
Published: (2016-06-01)

Super active surveillance for low-risk prostate cancer | Opinion: No
by: Saum Ghodoussipour, et al.

Super active surveillance for low-risk prostate cancer | Opinion: Yes
by: Leonardo O. Reis, et al.

Current status of active surveillance in prostate cancer
by: Mun Su Chung, et al.
Published: (2016-01-01)

A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
by: Sang Hun Song, et al.
Published: (2021-01-01)

Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up
by: Ji Yong Ha, et al.
Published: (2017-05-01)

Predicting Insignificant Prostate Cancer: Analysis of the Pathological Outcomes of Candidates for Active Surveillance according to the Pre-International Society of Urological Pathology (Pre-ISUP) 2014 Era Versus the Post-ISUP2014 Era
by: Mun Su Chung, et al.
Published: (2021-07-01)

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy
by: Wan Song, et al.
Published: (2019-11-01)

The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance
by: Chang Wook Jeong, et al.
Published: (2014-12-01)

MRI should be routine for all patients with localized prostate cancer? | Opinion: No
by: Joel B. Nelson

MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes
by: Ronaldo Hueb Baroni

Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?
by: Omer Gokhan Doluoglu, et al.
Published: (2016-04-01)

The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6
by: Hanfeng Wang, et al.
Published: (2017-09-01)

Comparison of positive surgical margin rates in high risk prostate cancer: open versus minimally invasive radical prostatectomy
by: Niall J. Harty, et al.
Published: (2013-09-01)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
by: Monica Vidal, et al.

PCA3 rs544190G>A and prostate cancer risk in an eastern Chinese population
by: Dalong Cao, et al.

PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples
by: Alberto A. Antunes, et al.
Published: (2013-09-01)

Prostate cancer in renal transplant recipients
by: Benjamin A. Sherer, et al.

Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions
by: Bashir Al Hussein Al Awamlh, et al.
Published: (2021-05-01)

Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
by: Min Ji Jeon, et al.
Published: (2021-08-01)

miR–483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5
by: Zhi-Gang Yang, et al.

Active surveillance for nonmuscle invasive bladder cancer
by: Makito Miyake, et al.
Published: (2016-06-01)

Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort
by: Elton Trigo Teixeira Leite, et al.

Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: YES
by: Luiz Otavio Torres

Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? | Opinion: Not Yet
by: Marcelo Langer Wroclawski, et al.

Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years
by: Marlon Perera, et al.
Published: (2016-03-01)

Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer
by: Jung Ki Jo, et al.
Published: (2015-04-01)

Prostatic Inflammation in Prostate Cancer: Protective Effect or Risk Factor?
by: Alessandro Tafuri, et al.
Published: (2021-06-01)

Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review
by: Andre Deeke Sasse, et al.

Active Surveillance—Is It Feasible for Intermediate-risk Localised Prostate Cancer?
by: Subhabrata Mukherjee, et al.
Published: (2021-02-01)

Evaluation of PCA3 and multiparametric MRI’s: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL
by: Sezgin Okcelik, et al.
Published: (2016-06-01)

Waiting times for prostate cancer: a review
by: Giacomo Lazzeri, et al.
Published: (2020-06-01)

Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
by: Ho Won Kang, et al.
Published: (2016-01-01)

Prostate cancer recurrence in vas deferens – fusion image guide as an important tool in dignosis
by: Leonardo Guedes Moreira Valle, et al.

Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance
by: Zambrano Norman, et al.
Published: (2014-04-01)

Focal therapy will be the next step on prostate cancer management? | Opinion: No
by: Wagner Eduardo Matheus, et al.

Cytoreductive surgery for men with metastatic prostate cancer
by: Nikolas Katelaris, et al.
Published: (2016-09-01)

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
by: Nikola Cihoric, et al.
Published: (2018-06-01)

Focal therapy will be the next step on prostate cancer management? | Opinion: Yes
by: Stênio de Cássio Zequi

Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma
by: Rutvij A. Khanolkar, et al.
Published: (2021-09-01)

Cannot write session to /tmp/vufind_sessions/sess_ublhikhduutncl78mf41421r8p